Regulatory challenges and current policy for cardiotoxicity detection in oncology drug development

Area of Science:

• Cardio-Oncology
• Regulatory Science
• Drug Development

Background:

• Rapid advancements in oncology therapeutics (targeted agents, antibody-drug conjugates, immunotherapies) have outpaced current regulatory frameworks for managing cardiotoxicity.
• Existing regulatory gaps include inconsistent cardiac safety requirements, limited integration of Cardio-Oncology endpoints in expedited pathways, and inadequate post-marketing surveillance.

Purpose of the Study:

• To review and evaluate the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval processes for oncology therapeutics.
• To identify limitations in current regulatory frameworks for detecting and managing drug-induced cardiotoxicity, particularly within expedited approval pathways.

Main Methods:

• Review of FDA and EMA approval processes, including expedited pathways (Breakthrough Therapy, Accelerated Approval, PRIME).
• Analysis of upstream activities in pivotal trials and post-marketing surveillance strategies.
• Examination of regulatory requirements for cardiac safety and Cardio-Oncology endpoints.

Main Results:

• Expedited pathways demonstrate strengths in pre-approval safety assessment and reducing time-to-therapy.
• Limitations identified include insufficient pre-approval cardiac phenotyping and reliance on surrogate endpoints for cardiotoxicity.
• Post-market surveillance infrastructures are constrained, delaying comprehensive understanding of long-term safety and efficacy.

Conclusions:

• A modernized, system-level approach integrating regulatory science with real-world cardiovascular risk is needed.
• Enhanced pre-approval cardiac assessment and robust post-marketing surveillance are essential for patient-centered drug development.
• Harmonization of regulatory requirements is critical for effective management of cardiotoxicity in the evolving landscape of oncology therapeutics.